Creabilis Itching To Start Phase III Tests Of Lead Asset For Chronic Pruritus

Keen to make up for lost time, dermatology specialist Creabilis Ltd is using positive Phase IIb data to advance its lead anti-itch product CT327, a novel topical TrkA kinase inhibitor, on to Phase III trials in psoriasis patients which, if successful, should open the way for regulatory filing in mid-2018 for a condition where there is no approved standard of care.